Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q2 2026 Earnings Presentation
22 slides from Arcticzymes Technologies Asa's earnings presentation, Aug 14, 2026
Slide 1: Q2 2026 Execution of Strategy delivers growth
August 14, 2026 Q2 2026 CEO Michael Akoh CFO Børge Sørvoll Execution of Strategy CCO Paul Blackburn delivers growth
Slide 2: Agenda
Agenda 1 Q2 Highlights and Strategy 2 Commercial Update 3 Financial Performance 4 Outlook and summary 5 Q&A
Slide 3: Execution of Strategy delivers strong Q2 and H1
Q2 2026 · HIGHLIGHTS Execution of Strategy delivers strong Q2 and H1 FINANCIAL PERFORMANCE MILESTONES CDMO ADOPTATION TOTAL REVENUE SALES REVENUE EBITDA CDMO Platform Validation M- SAN adopted on new CDMO platform 33.9 MNOK 31.9 MNOK Constant Exchange Rates 7.4 MNOK MOLECULAR TESTING 34.6 MNOK · +29
Slide 4: Strategy
Strategy
Slide 5: Strategic Pillars
Building a Scalable Enzyme Platform Strategic pillars accelerating growth and resilience Umbrella Strategy Customer focused market approach Transition from product-oriented enzyme supplier, to a customer centric, application lead/solutions provider Create a wider base – diversification Increase the
Slide 6: Commercial Update Q2 2026
Commercial Update Q2 2026
Slide 7: Q2 2026 Sales Highlights
Q2 2026 Sales Highlights Largest Q2 Revenue outside covid Q2 2026 Sales Revenue 31.9 MNOK 34.6 MNOK CER +19% YoY +5.1 MNOK vs Q2 2025 12 Month Average Sales (MNOK) Total Sales (MNOK) Record Q2 revenues; Growth path Strong trajectory; Revenue turnaround
Slide 8: Biomanufacturing
Biomanufacturing Record GMP Quarter - Sequential Growth Biomanufacturing 15.9 MNOK -12% YoY +6% QoQ Biomanufacturing Sales (MNOK) GMP Sales (MNOK) Growth Path; Strong adoption Use in clinical manufacturing 2
Slide 9: Molecular Tools
Molecular Tools Healthy Underlying Demand Molecular Tools 16.0 MNOK +84% YoY Molecular Tools Sales (MNOK) 12 Month Average Sales (MNOK) Application diversity; broad based growth Strong strategy leading to growth path 2
Slide 10: H1 2026 – Growth with Quality
H1 2026 – Growth with Quality Two quarters of strong revenue growth Total Sales Q1 and Q2 Revenues 63.7 MNOK 27% growth YoY 2025 37% 19% (50% CER) (29% CER) 39% CER Molecular Tools Biomanufacturing 32.5 MNOK 31.2 MNOK 78% growth YoY 2025 -2% YoY 2025 10
Slide 11: Inclusion in a High-Growth Cancer Screening Platform
Inclusion in a High-Growth Cancer Screening Platform Multi-year diagnostic partnership approaching regulatory decision and revenue ramp Company Track Record ✓ Commercial stage - scale-up order placed for autumn 2026 AZ Proteinase is embedded in a high-growth liquid- biopsy workflow - an enabler of t
Slide 12: European CDMO adopts M-SAN GMP for in vivo Car-T
European CDMO adopts M-SAN GMP for in vivo Car-T Southern European CDMO supply agreement and fast adoption of GMP Late Clinical Unlocked by GMP ✓ First purchase order placed at Q2 close; fast moving Consideration and inclusion demanded our GMP launch. Estimated this market will be market ✓ H2 foreca
Slide 13: Inclusion of M-SAN in US large pharma clinical trial
Inclusion of M-SAN in US large pharma clinical trial Cell and Gene Therapy ecosystem win M-SAN adopted via acquisition ✓ A start-up relationship has improved access to a global pharma. M-SAN HQ was specified pre-clinically by an SME and then retained through acquisition. Now progressing into ✓ Doubl
Slide 14: Financial Performance
Financial Performance A. ArcticZymes 424 Technolo: gies
Slide 15: Currency impact
USD/NOK Currency impact 12 11,5 Volatility in the market 11 10,5 10 Norwegian krone weakened against the USD and 9,5 the Euro in Q2 2026, but still stronger than Q2 9 2025 2024 2025 2026 EUR/NOK Norwegian krone is more or less flat against USD 12,2 and EURO in 2026 but still on stronger than 1H 12 2
Slide 16: Revenue growth outpacing cost growth
Revenue growth outpacing cost growth Commercial execution prioritised Q2 YTD Personnel expenses Sales revenues 2026 31,9 2025 26,8 2026 63,7 2025 50,0 Continued reduction in capitalization Other revenues 2,1 2,1 5,3 3,8 Sum revenues 33,9 28,9 69,0 53,8 Full effect of 2025 commercial hires driving to
Slide 17: Operating leverage coming through
Operating leverage coming through EBITDA nearly doubled Sales & EBITDA Q2 YTD 2026 2025 2026 2025 Sales EBITDA Sales revenues 31,9 26,8 63,7 50,0 35 Other revenues 2,1 2,1 5,3 3,8 Sum revenues 33,9 28,9 69,0 53,8 30 Cost of materials -0,9 -1,5 -2,3 -2,8 25 Change in inventory -0,7 0,0 -1,4 0,3 Perso
Slide 18: Cash flow and short-term investments
Cash flow and short-term investments Robust 269 MNOK position secures commercial execution Cash and STI position 30 290 Short term investments (STI) Net Cash (MNOK) Changes in Cash and STI (MNOK) 25 270 20 Changes in cash and STI (MNOK) 250 Net Cash (MNOK) 15 230 10 210 5 190 170 0 150 -5 Q1 2025 Q2
Slide 19: Outlook and Summary
Outlook and Summary
Slide 20: Driving Scalable Profitable Growth
Driving Scalable Profitable Growth Financial ambition. Disciplined focused execution. OUR AMBITION OUR EXECUTION Core priorities (2026-2028): Sustainable double-digit growth, targeting outperformance of served markets: Scale a high-performance commercial engine Innovation through internal R&D an
Slide 21: In Summary
In Summary The strategy is delivering and meaningful growth opportunities lie ahead GROWTH +27% Half-year sales growth, +39% at CER P R O F I T AB I L I T Y NOK 9.0m Half-year EBITDA, from NOK 0.1m a year ago L E V E R AG E +19% / +6% Sales growth against operating expense growth in Q2 STRENGTH NOK
Slide 22: Thank you Q & A
ArcticZymes Technologies *
ArcticZymes Technologies — Q2 2026 Earnings Presentation on 6ix